In our present study, we have utilized APP-complexed oncolytic Ad co-expressing IL-12 and GM-CSF (oAd/APP) in combination with DC to enhance the delivery of PTX and oncolytic Ad to tumor tissue, improve DC function, and subsequently induce potent antitumor effect by conjoining oncolytic Ad, chemotherapeutic, and immunotherapeutic. This evidence concerns the gene CSF2 and neoplasm.